Literature DB >> 23539274

[Integrated care in pain therapy: innovations and coordinated treatment offers from the "Techniker Krankenkasse"].

J Brunkhorst1, F Schwarz, S Klein.   

Abstract

Sectorally segregated healthcare structures are seen as a major reason for deficits in quality and efficiency. With the introduction of §§ 140 a ff. SGB V, the sectoral splitting into outpatient, inpatient and rehabilitative services will be eliminated. This is especially true for the requirements of state-of-the-art multidisciplinary and comprehensive pain therapy. Through this form of contract competition and competition for the best idea, incentives shall be created for economic behaviour of market participants, above all the efficient use of limited resources and allocation of healthcare resources based on need. Selective contracts are essential competition parameters for continued innovative development of the healthcare system. They enable statutory healthcare providers to offer their insurants innovative treatments which are not available in standard care. Agreements can be made concerning higher levels of quality and healthcare services, incentives for economical behaviour and success-based payment models. The key idea is the orientation on the needs of the insurant. The successful realisation of innovation in pain therapy is described using a practical example. Professional contractual partners, high quality information and communication, the taking over of responsibility for treatment and cost effectiveness are factors essential the success of innovative treatment concepts.

Entities:  

Mesh:

Year:  2013        PMID: 23539274     DOI: 10.1007/s00482-013-1303-4

Source DB:  PubMed          Journal:  Schmerz        ISSN: 0932-433X            Impact factor:   1.107


  1 in total

1.  [Development and implementation of integrated health care in pain medicine : the nationwide German headache treatment network].

Authors:  H Göbel; A Heinze; K Heinze-Kuhn; K Henkel; A Roth; H-H Rüschmann
Journal:  Schmerz       Date:  2009-12       Impact factor: 1.107

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.